Embecta (EMBC) to Release Quarterly Earnings on Thursday

Embecta (NASDAQ:EMBC) is scheduled to be releasing its earnings data before the market opens on Thursday, May 9th. Analysts expect Embecta to post earnings of $0.43 per share for the quarter. Embecta has set its FY 2024 guidance at 1.950-2.150 EPS.Parties interested in registering for the company’s conference call can do so using this link.

Embecta (NASDAQ:EMBC) last posted its quarterly earnings results on Friday, February 9th. The company reported $0.61 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.46 by $0.15. The company had revenue of $277.30 million for the quarter, compared to analyst estimates of $264.92 million. Embecta had a net margin of 4.93% and a negative return on equity of 18.66%. The company’s quarterly revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.93 earnings per share. On average, analysts expect Embecta to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Embecta Price Performance

Embecta stock opened at $10.39 on Tuesday. Embecta has a one year low of $9.93 and a one year high of $32.00. The firm has a market capitalization of $598.26 million, a P/E ratio of 10.94 and a beta of 0.86. The business has a fifty day moving average price of $12.20 and a 200-day moving average price of $15.21.

Embecta Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, March 15th. Stockholders of record on Wednesday, February 28th were given a dividend of $0.15 per share. This represents a $0.60 annualized dividend and a dividend yield of 5.77%. The ex-dividend date of this dividend was Tuesday, February 27th. Embecta’s dividend payout ratio is presently 63.16%.

Insiders Place Their Bets

In other Embecta news, Director David F. Melcher acquired 2,000 shares of the stock in a transaction dated Monday, February 12th. The stock was purchased at an average cost of $16.25 per share, for a total transaction of $32,500.00. Following the acquisition, the director now owns 45,080 shares in the company, valued at approximately $732,550. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.28% of the company’s stock.

Embecta Company Profile

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.